Slow platelet recovery after PBPC transplantation from unrelated donors

Bone Marrow Transplantation

Volumn 43, Issue 6, 2009, Pages 499-505

  Jansen, J ^a   Hanks, S G ^a   Akard, L P ^a   Morgan, J A ^a   Nolan, P L ^a   Dugan, M J ^a   Reeves, M I ^a   Thompson, J M ^a  

^a St Francis Hospital & Health Centers   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GENZYME; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BLOOD DONOR; BURST FORMING UNIT E; CD34 SELECTION; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLONY FORMING UNIT GM; CONTROLLED STUDY; DONOR SELECTION; ENGRAFTMENT; ERYTHROCYTE COUNT; FEMALE; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPOIESIS; WHOLE BODY RADIATION;

ADULT; AGED; ANTIGENS, CD34; BLOOD PLATELETS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEUTROPHILS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLATELET COUNT; STEM CELLS; TEMPERATURE; TREATMENT OUTCOME;

EID: 63949086376     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.346     Document Type: Article

References (18)

1. Bacigalupo A, Frassoni F, Van Lint M. Bone marrow or peripheral blood as a source of stem cells for allogeneic transplants. Curr Opin Hematol 2000; 7: 343-347.
2. Cutler C, Antin JH. Peripheral blood stem cells for allogeneic transplantation: A review. Stem Cells 2001; 19: 108-117.
3. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al Transplantation of bone marrow as compared to peripheral blood cells from HLA-identical relatives in patients with hematologic cancer. N Engl J Med 2001; 344: 175-181.
4. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: An individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074-5087.
5. BMT CTN. A phase III randomized multi-center trial comparing G-CSF mobilized peripheral blood stem cell with marrow transplantation from HLA-compatible unrelated donors. http://web.emmes.com/study/bmt/protocol/ 0201_protocol/0201_protocol.html.
6. Haynes A, Hunter A, McQuaker G, Anderson S, Bienz N, Russell NH. Engraftment characteristics of peripheral blood stem cells mobilized with cyclophosphamide and the delayed addition of G-CSF. Bone Marrow Transplant 1995; 16: 359-363.
7. + peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998; 4: 84-92.
8. Jansen EM, Hanks SG, Terry C, Akard LP, Thompson JM, Dugan MJ et al Prediction of engraftment after autologous peripheral blood progenitor cell transplantation: CD34, CFUGM, or both? Transfusion 2007; 47: 817-823.
9. Weaver CH, Hazelton B, Burch B, Palmer P, Allen C, Schwarzenberg L et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
10. Anderlini P, Körbling M. The use of mobilized peripheral blood stem cells from normal donors for allografting. Stem Cells 1997; 15 9-17.
11. Miffin G, Russell NH, Hutchinson RM, Morgan G, Potter M, Pagliuca A et al. Allogeneic peripheral blood stem cell transplantation for haematological malignancies - an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant 1997; 19: 9-13.
12. Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C et al. CD34+ cells dose predicts survival, post-transplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223-3229.
13. Urbano-Ispizua A, Solano C, Brunet S, Hernandez F, Sanz G, Alegre A et al. Allogeneic peripheral blood progenitor cell transplantation: analysis of short-term engraftment and acute GVHD incidence in 33 cases. Bone Marrow Transplant 1996; 18: 35-40.
14. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419-2425.
15. Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U et al Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant 2005; 35: 1089-1093.
16. Davies SM, Kollman C, Anasetti C, Antin JH, Gajewski J, Casper JT et al. Engraftment and survival after unrelated-donor bone marrow transplantation: A report from the National Marrow Donor Program. Blood 2000; 96: 4096-4102.
17. Stroncek DF, Confer DL, Leitman SF. Peripheral blood progenitor cells for HPC transplants involving unrelated donors. Transfusion 2000; 40: 731-741.
18. Anderlini P, Lauppe J, Przepiorka D, Seong D, Champlin R, Korbling M. Peripheral blood stem cell apheresis in normal donors: Feasibility and yield of second collections. Br J Haematol 1997; 96: 415-417.